PL3558981T3 - Pochodne piranu jako inhibitory cyp11a1 (monooksygenazy 11a1 cytochromu p450) - Google Patents
Pochodne piranu jako inhibitory cyp11a1 (monooksygenazy 11a1 cytochromu p450)Info
- Publication number
- PL3558981T3 PL3558981T3 PL17832250T PL17832250T PL3558981T3 PL 3558981 T3 PL3558981 T3 PL 3558981T3 PL 17832250 T PL17832250 T PL 17832250T PL 17832250 T PL17832250 T PL 17832250T PL 3558981 T3 PL3558981 T3 PL 3558981T3
- Authority
- PL
- Poland
- Prior art keywords
- cyp11a1
- piran
- monooxygenases
- cytochrome
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20166024 | 2016-12-22 | ||
| EP17832250.9A EP3558981B1 (en) | 2016-12-22 | 2017-12-21 | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
| PCT/FI2017/050926 WO2018115591A1 (en) | 2016-12-22 | 2017-12-21 | Pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3558981T3 true PL3558981T3 (pl) | 2021-12-06 |
Family
ID=61005837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17832250T PL3558981T3 (pl) | 2016-12-22 | 2017-12-21 | Pochodne piranu jako inhibitory cyp11a1 (monooksygenazy 11a1 cytochromu p450) |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US10717726B2 (OSRAM) |
| EP (2) | EP3558981B1 (OSRAM) |
| JP (2) | JP7025432B2 (OSRAM) |
| KR (3) | KR102491308B1 (OSRAM) |
| CN (2) | CN116162084B (OSRAM) |
| AR (1) | AR110412A1 (OSRAM) |
| AU (2) | AU2017380282B2 (OSRAM) |
| CA (1) | CA3047370A1 (OSRAM) |
| CL (1) | CL2019001728A1 (OSRAM) |
| CO (1) | CO2019007321A2 (OSRAM) |
| CY (1) | CY1124461T1 (OSRAM) |
| DK (1) | DK3558981T3 (OSRAM) |
| EA (1) | EA039309B1 (OSRAM) |
| ES (1) | ES2880151T3 (OSRAM) |
| HR (1) | HRP20211255T1 (OSRAM) |
| HU (1) | HUE056540T2 (OSRAM) |
| IL (2) | IL267484B (OSRAM) |
| LT (1) | LT3558981T (OSRAM) |
| MA (2) | MA47102B1 (OSRAM) |
| MX (1) | MX388538B (OSRAM) |
| NZ (1) | NZ755395A (OSRAM) |
| PE (1) | PE20191137A1 (OSRAM) |
| PH (1) | PH12019550111A1 (OSRAM) |
| PL (1) | PL3558981T3 (OSRAM) |
| PT (1) | PT3558981T (OSRAM) |
| RS (1) | RS62198B1 (OSRAM) |
| SI (1) | SI3558981T1 (OSRAM) |
| TN (1) | TN2019000189A1 (OSRAM) |
| TW (2) | TWI762544B (OSRAM) |
| UA (1) | UA124640C2 (OSRAM) |
| WO (1) | WO2018115591A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110412A1 (es) * | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
| WO2021229152A1 (en) | 2020-05-14 | 2021-11-18 | Orion Corporation | Cyp11a1 inhibitors |
| KR20230117187A (ko) | 2020-12-01 | 2023-08-07 | 오리온 코포레이션 | 전립선암 치료를 위한 cyp11a1 억제제로서 2,3-디히드로-4h-벤조[b][1,4]옥사진-4-일)(5-(페닐)-피리딘-3-일)메타논유도체 및 유사 화합물 |
| CA3210591A1 (en) * | 2021-03-01 | 2022-09-09 | Oskari KARJALAINEN | Process for the preparation of a cyp11a1 inhibitor and intermediates thereof |
| AR124985A1 (es) | 2021-03-01 | 2023-05-24 | Orion Corp | Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona |
| JP2024511296A (ja) | 2021-03-01 | 2024-03-13 | オリオン・コーポレーション | ４ｈ－ピラン－４オンの構造を有するｃｙｐ１１ａ１阻害薬の固体形態 |
| IL309484A (en) | 2021-06-23 | 2024-02-01 | Orion Corp | A process for preparing a CYP11A1 inhibitor and its intermediates |
| EP4408426A1 (en) * | 2021-09-28 | 2024-08-07 | Orion Corporation | Cyp11a1 inhibitor for use in the treatment of prostate cancer |
| WO2023073285A1 (en) | 2021-10-28 | 2023-05-04 | Orion Corporation | Salt forms of a 4h-pyran-4-one structured cyp11 at inhibitor |
| EP4430027A1 (en) | 2021-11-10 | 2024-09-18 | Orion Corporation | Cyp11a1 inhibitors |
| US20250099451A1 (en) | 2022-01-20 | 2025-03-27 | Orion Corporation | Pharmaceutical composition of a cyp11a1 inhibitor |
| JP7645296B2 (ja) * | 2022-02-08 | 2025-03-13 | ディーエヌエフ カンパニー リミテッド | ヨウ素含有金属化合物およびこれを含む薄膜蒸着用組成物 |
| CN118307519A (zh) | 2023-01-06 | 2024-07-09 | 上海闻耐医药科技有限公司 | 一类cyp11a1抑制剂化合物及其制备方法和用途 |
| KR20240126916A (ko) | 2023-02-14 | 2024-08-22 | 경북대학교 산학협력단 | Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물 |
| AU2024242063A1 (en) | 2023-03-29 | 2025-10-09 | Xizang Haisco Pharmaceutical Co., Ltd. | Cyp11a1 inhibitor and use thereof |
| KR20250173540A (ko) | 2023-04-21 | 2025-12-10 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | Cyp11a1 억제제 및 이의 용도 |
| WO2024230825A1 (en) * | 2023-05-11 | 2024-11-14 | Shenzhen Ionova Life Science Co., Ltd. | Novel compounds as cyp11a1 inhibitors and methods of use thereof |
| WO2025017072A1 (en) | 2023-07-19 | 2025-01-23 | Orion Corporation | Stable pharmaceutical compositions of a cyp11a1 inhibitor |
| WO2025021182A1 (en) * | 2023-07-27 | 2025-01-30 | Acerand Therapeutics (Hong Kong) Limited | Cyp11a1 inhibitors |
| WO2025051216A1 (zh) * | 2023-09-08 | 2025-03-13 | 深圳众格生物科技有限公司 | 一种cyp11a1抑制剂、其制备方法及其应用 |
| WO2025168117A1 (zh) * | 2024-02-08 | 2025-08-14 | 盛睿泽华医药科技（苏州）有限公司 | 一种多环化合物及其制备方法和应用 |
| WO2025237211A1 (zh) * | 2024-05-11 | 2025-11-20 | 辽宁海思科制药有限公司 | 一种cyp11a1抑制剂的晶型物及其制备方法和应用 |
| WO2025247149A1 (zh) * | 2024-05-27 | 2025-12-04 | 辽宁海思科制药有限公司 | 一种cyp11a1抑制剂的盐及其晶型、其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6176485A (ja) * | 1984-09-20 | 1986-04-18 | Ss Pharmaceut Co Ltd | 新規なγ−ピラン誘導体 |
| US7344700B2 (en) * | 2002-02-28 | 2008-03-18 | University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| EP1471063A1 (en) * | 2003-02-28 | 2004-10-27 | Exonhit Therapeutics S.A. | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| US20140005181A1 (en) * | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| TW201534586A (zh) * | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎ｃｙｐ１７抑制劑／抗雄激素劑 |
| AR110412A1 (es) * | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
-
2017
- 2017-12-20 AR ARP170103609A patent/AR110412A1/es active IP Right Grant
- 2017-12-21 KR KR1020197021256A patent/KR102491308B1/ko active Active
- 2017-12-21 SI SI201730841T patent/SI3558981T1/sl unknown
- 2017-12-21 PE PE2019001297A patent/PE20191137A1/es unknown
- 2017-12-21 CN CN202211597796.4A patent/CN116162084B/zh active Active
- 2017-12-21 EA EA201991513A patent/EA039309B1/ru unknown
- 2017-12-21 TW TW106145006A patent/TWI762544B/zh active
- 2017-12-21 CN CN201780079479.4A patent/CN110139861B/zh active Active
- 2017-12-21 PT PT178322509T patent/PT3558981T/pt unknown
- 2017-12-21 PL PL17832250T patent/PL3558981T3/pl unknown
- 2017-12-21 AU AU2017380282A patent/AU2017380282B2/en active Active
- 2017-12-21 US US16/472,377 patent/US10717726B2/en active Active
- 2017-12-21 RS RS20210994A patent/RS62198B1/sr unknown
- 2017-12-21 DK DK17832250.9T patent/DK3558981T3/da active
- 2017-12-21 HU HUE17832250A patent/HUE056540T2/hu unknown
- 2017-12-21 TW TW111114824A patent/TWI796205B/zh active
- 2017-12-21 LT LTEP17832250.9T patent/LT3558981T/lt unknown
- 2017-12-21 TN TNP/2019/000189A patent/TN2019000189A1/en unknown
- 2017-12-21 MA MA47102A patent/MA47102B1/fr unknown
- 2017-12-21 ES ES17832250T patent/ES2880151T3/es active Active
- 2017-12-21 KR KR1020237002074A patent/KR102826021B1/ko active Active
- 2017-12-21 MX MX2019007373A patent/MX388538B/es unknown
- 2017-12-21 KR KR1020257020993A patent/KR20250097993A/ko active Pending
- 2017-12-21 JP JP2019534192A patent/JP7025432B2/ja active Active
- 2017-12-21 NZ NZ755395A patent/NZ755395A/en unknown
- 2017-12-21 WO PCT/FI2017/050926 patent/WO2018115591A1/en not_active Ceased
- 2017-12-21 EP EP17832250.9A patent/EP3558981B1/en active Active
- 2017-12-21 HR HRP20211255TT patent/HRP20211255T1/hr unknown
- 2017-12-21 CA CA3047370A patent/CA3047370A1/en active Pending
- 2017-12-21 EP EP21165964.4A patent/EP3868756A1/en not_active Withdrawn
- 2017-12-21 MA MA055983A patent/MA55983A/fr unknown
- 2017-12-21 UA UAA201908272A patent/UA124640C2/uk unknown
-
2019
- 2019-06-19 IL IL267484A patent/IL267484B/en unknown
- 2019-06-20 CL CL2019001728A patent/CL2019001728A1/es unknown
- 2019-06-21 PH PH12019550111A patent/PH12019550111A1/en unknown
- 2019-07-09 CO CONC2019/0007321A patent/CO2019007321A2/es unknown
-
2020
- 2020-06-08 US US16/895,221 patent/US11098032B2/en active Active
-
2021
- 2021-05-28 AU AU2021203497A patent/AU2021203497B2/en active Active
- 2021-07-06 US US17/367,849 patent/US12030871B2/en active Active
- 2021-08-19 IL IL285729A patent/IL285729B/en unknown
- 2021-08-25 CY CY20211100760T patent/CY1124461T1/el unknown
-
2022
- 2022-02-10 JP JP2022019891A patent/JP7286825B2/ja active Active
-
2024
- 2024-05-24 US US18/674,603 patent/US20240308989A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3558981T3 (pl) | Pochodne piranu jako inhibitory cyp11a1 (monooksygenazy 11a1 cytochromu p450) | |
| IL269216A (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| DK3687999T3 (da) | Rapamycinderivater | |
| ZA201808639B (en) | Pyrazole derivatives as plasma kallikrein inhibitors | |
| EP3558969C0 (en) | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | |
| LT3710446T (lt) | Junginiai, naudingi cdk7 slopinimui | |
| DK3445767T3 (da) | Makrocykliske mcl1-inhibitorer til behandling af cancer | |
| DK3119762T3 (da) | Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft | |
| MA43753A (fr) | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu | |
| TWI800498B (zh) | 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物 | |
| MA39823A (fr) | Dérivés de pyridine macrocyclique | |
| EP3883573A4 (en) | DYRK1A MACROCYCLIC INHIBITORS | |
| PT3334744T (pt) | Complexos de anel penta-aza macrocíclico que possuem biodisponibilidade oral | |
| DK3279187T3 (da) | 9-leddet fusioneret ringderivat | |
| HUE045651T2 (hu) | Eljárás rapamicin-származékok szintézisére | |
| DK3898637T3 (da) | Rapamycin-derivater | |
| EP3615525C0 (en) | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | |
| IL264292A (en) | Advanced oxidative process for microbial reduction | |
| EP3526216C0 (en) | BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS | |
| LT3280721T (lt) | Azoto iprito darinių gavimo būdas | |
| EP3400220A4 (en) | PYRAZOLE DERIVATIVES | |
| DK3484875T3 (da) | Pyrazolylaminobenzimidazolderivater som JAK-hæmmere | |
| DK3331873T3 (da) | 4-(3-pyrazolylamino)-benzimidazolderivat som jak1-inhibitor til behandling af kræft | |
| HK40093308A (zh) | 作为cyp11a1抑制剂的吡喃衍生物 | |
| HK40006442A (en) | Derivatives of sobetirome |